SAN FRANCISCO, April 21, 2021 The global primary cell culture market size is expected to reach USD 8.0 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.6% from 2021 to 2028.
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics Adds unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa Broadens SparingVisions innovative genomic medicine pipeline to address both mid and late stages of rod-cone dystrophies with the added potential to combine both products SparingVisions m...
Video message details merger closing process following completion of the April 23 virtual Special Meeting as well as next planned milestones for the merged company to be renamed Palisade Bio As of April 19, 2021, based on voting indications, Proposal 1 is expected to be approved at the Special Meeting completing the transaction.
BALTIMORE---- Akers Biosciences, Inc. (AKER) and MyMD Pharmaceuticals, Inc. today announced that at Akers’ special meeting of stockholders held on April 15, 2021, Akers obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Akers and MYMD.
SALT LAKE CITY, April 16, 2021 Desert Highlands Regenerative, a private equity group, has acquired a majority ownership of APEX Biologix, the designers and manufacturers of the XCELL Platelet-Rich Plasma and other regenerative medicine products.
Offeror), Sanofi and Kiadis Pharma N.V. in connection with the public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis.
Inotiv, Inc. (NOTV), a leading provider of non-clinical and analytical contract research services, today announced that the Company has entered into an agreement and plan of merger with Bolder BioPATH, Inc., a contract pharmacology and pathology company specializing in in vivo models of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, diseases of the central nervous system and other a...
THOUSAND OAKS, Calif. "Five Prime fits squarely within Amgen's (AMGN) leading oncology portfolio and includes bemarituzumab, a Phase 3 trial-ready, first-in-class program for gastric cancer, the third leading cause of cancer mortality worldwide," said Robert A. Bradway, chairman and chief executive officer at Amgen.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
